Om

BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for neuroscience and immuno-oncology using artificial intelligence and data-driven drug discovery. Its current portfolio includes IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, as well as investigational programs built around BXCL501 and other proprietary candidates. The company’s neuroscience work addresses conditions such as agitation in dementia and major depressive disorder, while its immuno-oncology efforts are centered on oral immune-activating therapies for aggressive cancers through its subsidiary, OnkosXcel Therapeutics. Headquartered in New Haven, Connecticut, BioXcel Therapeutics operates as a commercial-stage specialty biotechnology company with a focus on advancing targeted treatment options in areas with significant unmet medical need.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I BIOXCEL THERAPEUTICS MED ENDAVU: Køb Bioxcel Therapeutics ($BX20) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Bioxcel Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.